Breaking News

PDL BioPharma Sells Noden Pharma for $48.3M

Noden Pharma DAC is a global specialty pharmaceutical company focused on acquiring prescription medicines across a broad range of therapeutic areas.

By: Contract Pharma

Contract Pharma Staff

PDL BioPharma, Inc. has signed a definitive agreement to sell its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively Noden) to Stanley Capital in a transaction of up to $48.25 million in cash. The transaction is expected to close in August 2020, subject to certain customary closing conditions. “Entering into this transaction for the sale of Noden to Stanley Capital represents another significant step in the execution of our monetization strategy,” commented PDL...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters